Matinas BioPharma Holdings, Inc. announced the appointment of Hui Liu as Chief Technology Officer. Dr. Liu joins Matinas with extensive experience in pharmaceutical formulation and delivery technologies, including lipid nanoparticle formulations of mRNA, siRNA and vaccines. In this new role, Dr. Liu will work closely with Raphael Mannino, Ph.D., Matinas’ Chief Scientific Officer, and lead efforts to further strengthen the Company’s proprietary lipid nanocrystal drug delivery platform and accelerate its potential applications for both internal programs and external collaborations. Dr. Liu has more than two decades of experience in the formulation of small molecules, biologics, and gene therapies. Dr. Liu joins Matinas directly from Seqirus, where he served as Director of Formulation and Delivery.